Moleculin Biotech (MBRX) Debt to Equity (2017 - 2022)
Moleculin Biotech (MBRX) has 6 years of Debt to Equity data on record, last reported at $0.0 in Q4 2022.
- For Q4 2022, Debt to Equity rose 19.42% year-over-year to $0.0; the TTM value through Dec 2022 reached $0.0, up 19.42%, while the annual FY2022 figure was $0.0, 19.42% up from the prior year.
- Debt to Equity reached $0.0 in Q4 2022 per MBRX's latest filing, down from $0.0 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.36 in Q3 2019 and bottomed at $0.0 in Q1 2021.
- Average Debt to Equity over 5 years is $0.06, with a median of $0.01 recorded in 2020.
- Peak YoY movement for Debt to Equity: surged 1358.04% in 2019, then tumbled 98.1% in 2020.
- A 5-year view of Debt to Equity shows it stood at $0.01 in 2018, then crashed by 49.59% to $0.01 in 2019, then crashed by 30.92% to $0.0 in 2020, then plummeted by 68.58% to $0.0 in 2021, then increased by 19.42% to $0.0 in 2022.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.0 in Q4 2022, $0.0 in Q3 2022, and $0.0 in Q2 2022.